1. Novel mutations in TNFRSF7/CD27: Clinical, immunologic, and genetic characterization of human CD27 deficiency.
- Author
-
Alkhairy OK, Perez-Becker R, Driessen GJ, Abolhassani H, van Montfrans J, Borte S, Choo S, Wang N, Tesselaar K, Fang M, Bienemann K, Boztug K, Daneva A, Mechinaud F, Wiesel T, Becker C, Dückers G, Siepermann K, van Zelm MC, Rezaei N, van der Burg M, Aghamohammadi A, Seidel MG, Niehues T, and Hammarström L
- Subjects
- Adolescent, Child, Preschool, Epstein-Barr Virus Infections diagnosis, Epstein-Barr Virus Infections immunology, Epstein-Barr Virus Infections pathology, Exome, Female, Flow Cytometry, Heterozygote, Hodgkin Disease diagnosis, Hodgkin Disease immunology, Hodgkin Disease pathology, Homozygote, Humans, Immunophenotyping, Infant, Lymphohistiocytosis, Hemophagocytic diagnosis, Lymphohistiocytosis, Hemophagocytic immunology, Lymphohistiocytosis, Hemophagocytic pathology, Lymphoproliferative Disorders diagnosis, Lymphoproliferative Disorders immunology, Lymphoproliferative Disorders pathology, Male, Tumor Necrosis Factor Receptor Superfamily, Member 7 deficiency, Tumor Necrosis Factor Receptor Superfamily, Member 7 immunology, Uveitis diagnosis, Uveitis immunology, Uveitis pathology, Young Adult, Epstein-Barr Virus Infections genetics, Hodgkin Disease genetics, Lymphohistiocytosis, Hemophagocytic genetics, Lymphoproliferative Disorders genetics, Mutation, Tumor Necrosis Factor Receptor Superfamily, Member 7 genetics, Uveitis genetics
- Abstract
Background: The clinical and immunologic features of CD27 deficiency remain obscure because only a few patients have been identified to date., Objective: We sought to identify novel mutations in TNFRSF7/CD27 and to provide an overview of clinical, immunologic, and laboratory phenotypes in patients with CD27 deficiency., Methods: Review of the medical records and molecular, genetic, and flow cytometric analyses of the patients and family members were performed. Treatment outcomes of previously described patients were followed up., Results: In addition to the previously reported homozygous mutations c.G24A/p.W8X (n = 2) and c.G158A/p.C53Y (n = 8), 4 novel mutations were identified: homozygous missense c.G287A/p.C96Y (n = 4), homozygous missense c.C232T/p.R78W (n = 1), heterozygous nonsense c.C30A/p.C10X (n = 1), and compound heterozygous c.C319T/p.R107C-c.G24A/p.W8X (n = 1). EBV-associated lymphoproliferative disease/hemophagocytic lymphohistiocytosis, Hodgkin lymphoma, uveitis, and recurrent infections were the predominant clinical features. Expression of cell-surface and soluble CD27 was significantly reduced in patients and heterozygous family members. Immunoglobulin substitution therapy was administered in 5 of the newly diagnosed cases., Conclusion: CD27 deficiency is potentially fatal and should be excluded in all cases of severe EBV infections to minimize diagnostic delay. Flow cytometric immunophenotyping offers a reliable initial test for CD27 deficiency. Determining the precise role of CD27 in immunity against EBV might provide a framework for new therapeutic concepts., (Copyright © 2015 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF